Log in to save to my catalogue

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome...

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fef037278a2f4851b867577c0a56cf60

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs

About this item

Full title

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs

Publisher

London: BioMed Central Ltd

Journal title

Journal of translational medicine, 2022-08, Vol.20 (1), p.1-371, Article 371

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Background Despite the increasing number of treatment options, reliable prognostic/predictive biomarkers are still missing for patients affected by metastatic clear cell renal cell carcinoma (mccRCC). Methods Patients with mccRCC undergoing standard first line treatment were enrolled. Blood (12 ml) was drawn at treatment baseline and circulating fr...

Alternative Titles

Full title

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_fef037278a2f4851b867577c0a56cf60

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fef037278a2f4851b867577c0a56cf60

Other Identifiers

ISSN

1479-5876

E-ISSN

1479-5876

DOI

10.1186/s12967-022-03557-7

How to access this item